Drug Profile
Research programme: thrombosis/dementia therapeutics - Institute of Medicinal Molecular Design
Alternative Names: IMD-4852Latest Information Update: 28 May 2013
Price :
$50
*
At a glance
- Originator Institute of Medicinal Molecular Design
- Class
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Atherosclerosis; Thrombosis; Vascular dementia
Most Recent Events
- 28 May 2013 This research programme in thrombosis/dementia therapeutics is available for licensing as of 28 May 2013. http://www.immd.co.jp
- 28 May 2013 No development reported - Preclinical for Alzheimer's disease in Japan (PO)
- 28 May 2013 No development reported - Preclinical for Atherosclerosis in Japan (PO)